Absci (ABSI) Cash from Investing Activities (2020 - 2026)
Absci (ABSI) reported Cash from Investing Activities of $7.4 million for Q1 2026, up 148.94% on a YoY basis from $3.0 million in Q1 2025, and down 62.34% sequentially from $19.5 million in Q4 2025.
Absci (ABSI) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Absci (ABSI) has 7 years of Cash from Investing Activities data on file, last reported at $7.4 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 148.94% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at -$27.8 million (down 238.35% YoY), and the FY2025 full-year result was -$50.2 million, down 20.64% from the prior year.
- Cash from Investing Activities retreated to $7.4 million in Q1 2026, from $19.5 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $70.2 million in Q2 2023 to a low of -$78.7 million in Q3 2022.
- A 5-year average of -$7.6 million and a median of $1.3 million in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities plunged 1054.3% in 2022 and surged 725.07% in 2023, its largest moves.
- Tracing ABSI's Cash from Investing Activities over 5 years: stood at -$30.2 million in 2022, then surged by 162.82% to $19.0 million in 2023, then gained by 0.45% to $19.0 million in 2024, then advanced by 2.65% to $19.5 million in 2025, then plunged by 62.34% to $7.4 million in 2026.
- Business Quant data shows ABSI's Cash from Investing Activities at $7.4 million in Q1 2026, $19.5 million in Q4 2025, and -$63.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Absci | 1.17 Bn | 1.05 Bn | - | 7.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.36 Mn |
| Mar 31, 2026 | 7.36 Mn |
| Dec 31, 2025 | 19.55 Mn |
| Dec 31, 2025 | 19.55 Mn |
| Sep 30, 2025 | -63.70 Mn |
| Sep 30, 2025 | -63.70 Mn |
| Jun 30, 2025 | 9.04 Mn |
| Jun 30, 2025 | 9.04 Mn |
| Mar 31, 2025 | -15.04 Mn |
| Mar 31, 2025 | -15.04 Mn |
| Dec 31, 2024 | 19.04 Mn |
| Dec 31, 2024 | 19.04 Mn |
| Sep 30, 2024 | 14.81 Mn |
| Sep 30, 2024 | 14.81 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | -76.68 Mn |
| Mar 31, 2024 | -76.68 Mn |
| Dec 31, 2023 | 18.96 Mn |
| Dec 31, 2023 | 18.96 Mn |